The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
882
Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour "loading dose" of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
Favorable Outcome as Determined by the Glasgow Outcome Scale-Extended (GOSE)
A measure of functional recovery: A GOS-E score of 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery. Favorable outcome was defined via stratified dichotomy based on the severity of the initial injury. For subjects with a severe injury, a GOS-E of 3 or higher were considered to be a favorable outcome; for subjects with moderate-to-severe injury, a GOS-E of 5 or higher was considered to be a favorable outcome; for subjects with a moderate injury, a GOS-E of 7 or higher was considered to be a favorable outcome.
Time frame: 6 months post randomization
Mortality
Time frame: 6 months
Disability Rating Scale
A measure of functional impairment, with complete recovery scored a 0 and vegetative state scored a 29.
Time frame: 6 months
Potentially Associated Adverse Events: Phlebitis/Thrombophlebitis
Phlebitis/Thrombophlebitis (not due to infiltration or misplacement of the IV)
Time frame: within 6 months
Potentially Associated Adverse Events: Pulmonary Embolism
Pulmonary embolism - Events were defined based on either positive chest computed tomography (CT) scanning or ventilation/perfusion lung scan (V/Q).
Time frame: within 6 months
Potentially Associated Adverse Events: Acute Ischemic Stroke
Acute ischemic stroke - Events were defined based on either positive computed tomography (CT) scanning, magnetic resonance imaging (MRI), or neurologist diagnosis of cerebrovascular accident (CVA)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Maricopa Integrated Health System
Phoenix, Arizona, United States
Banner Good Samaritan
Phoenix, Arizona, United States
Scottsdale Healthcare
Scottsdale, Arizona, United States
University of Arizona Medical Center
Tuscon, Arizona, United States
Santa Clara Valley Hospital
Palo Alto, California, United States
Stanford Medical Center
Palo Alto, California, United States
San Francisco General Hospital
San Francisco, California, United States
Regional Medical Center-San Jose
San Jose, California, United States
Grady Memorial Hospital
Atlanta, Georgia, United States
University of Kentucky Medical Center
Lexington, Kentucky, United States
...and 26 more locations
Time frame: within 6 months
Potentially Associated Adverse Events: Deep Venous Thrombosis (DVT)
DVT - Events were defined based on a positive Doppler ultrasound exam
Time frame: within 6 months
Potentially Associated Adverse Events: Unexplained Increased Liver-enzyme Level
Unexplained increased liver enzymes (e.g. not due to liver injury ) - Events were defined based on aspartate transaminase (AST) and alanine transaminase (ALT) levels \> 500 U/L and/or total bilirubin levels \> 2.0 mg/dL.
Time frame: within 6 months
Potentially Associated Adverse Events: Sepsis
Sepsis - Events must have met Centers for Disease Control and Prevention (CDC) definition of sepsis. The definition includes that a patient ≤1 year of age has at least 1 of the following clinical signs or symptoms with no other recognized cause: fever (\>38°C rectal), hypothermia (\<37°C rectal), apnea, or bradycardia, and blood culture not done or no organisms detected in blood and no apparent infection at another site and physician institutes treatment for sepsis.
Time frame: within 6 months
Potentially Associated Adverse Events: Pneumonia
Events must have met Centers for Disease Control and Prevention (CDC) definition of pneumonia. There are three specific types of pneumonia: clinically defined pneumonia, pneumonia with specific laboratory findings, and pneumonia in immunocompromised patients. There are specific algorithms to identify each pneumonia, which include x-ray findings, fever with no other cause, leukopenia or leukocytosis, altered mental status with no other cause (adults \>70 years old), new onset of purulent sputum, change in character of sputum, increase respiratory secretions, increase suctioning requirements, new onset or worsening cough, dyspnea, tachypnea, rales, bronchial breath sounds, or worsening gas exchange, increased oxygen requirements, or increased ventilator demand). Also, labs can identify pneumonia such as positive growth in blood culture, positive Gram stain, and histopathologic exam evidence.
Time frame: within 6 months
Potentially Associated Adverse Events: Central Nervous System (CNS) Infection
CNS infection - Events must have met Centers for Disease Control and Prevention (CDC) definition of CNS infection. The definition includes intracranial infection, Meningitis, ventriculitis, and spinal abscess without meningitis.
Time frame: within 6 months
Potentially Associated Adverse Events: Myocardial Infarction (MI)
Myocardial infarction - Events were defined based on serial cardiac enzyme elevation consistent with MI and/or new ST elevation on electrocardiogram (ECG) consistent with MI. Potentially associated adverse events (those events which are included as outcome measures) were specifically defined per the protocol, and the classification of an event as a PAAE was determined by the site. The reported name of the associated event, however, was subject to clinical judgement and case details; these were then further coded by the Principal Investigator. Since these data points do not share the same definition, there is no reason to expect perfect concordance. (For example, the potentially associated adverse event of myocardial infarction may include MedDRA codes other than myocardial infarction.)
Time frame: within 6 months